Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Phase III by Year
Novartis Phase III: 36 in FY2025, up 12.5% from a year earlier.
Latest, FY2025
36
Period ended Dec 31, 2025
Change on a year earlier
+12.5%
32 in FY2024
History
5 years
Since FY2021
Sources
2
Documents cited below
Where the FY2025 figure comes from
“| Phase III | 36 | 32 | 34”
Source: Novartis Official IR / Sustainability Report — novartis-esg-data-summary-2025.pdf ↗
Reported in ESG Data Summary 2025 & Form 6-K Nonfinancial.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Phase III | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 36 | +12.5% | Novartis Official IR / Sustainability Report — novartis-esg-data-summary-2025.pdf ↗ |
| FY2024 | Dec 31, 2024 | 32 | -22.0% | Novartis Official IR / Sustainability Report — novartis-esg-data-summary-2025.pdf ↗ |
| FY2023 | Dec 31, 2023 | 41 | -2.4% | Novartis Form 6-K (0001370368-24-000008) ↗ |
| FY2022 | Dec 31, 2022 | 42 | -19.2% | Novartis Form 6-K (0001370368-24-000008) ↗ |
| FY2021 | Dec 31, 2021 | 52 | – | Novartis Form 6-K (0001370368-24-000008) ↗ |
Cite this data
StockData. (2026). Novartis Phase III, annual FY2021–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/rd-pipeline-ph3
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.